GEMOAB MONOCLONALS GMBH has a total of 33 patent applications. It increased the IP activity by 500.0%. Its first patent ever was published in 2010. It filed its patents most often in EPO (European Patent Office), United States and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are ALTOR BIOSCIENCE LLC, EUCURE BEIJING BIOPHARMA CO LTD and LYVGEN BIOPHARMA HOLDINGS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 10 | |
#2 | United States | 7 | |
#3 | Canada | 3 | |
#4 | China | 3 | |
#5 | Japan | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Germany | 1 | |
#8 | Hong Kong | 1 | |
#9 | Hungary | 1 | |
#10 | Israel | 1 | |
#11 | Republic of Korea | 1 | |
#12 | Serbia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Bachmann Michael | 22 |
#2 | Ehninger Armin | 17 |
#3 | Michael Bachmann | 2 |
#4 | Stamova Slava | 1 |
Publication | Filing date | Title |
---|---|---|
EP3581200A1 | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
CN110678198A | Targeting modules directed against immune cells expressing universal chimeric antigen receptors and their use in the treatment of cancer, infections and autoimmune disorders | |
EP3546567A1 | Genetic modified pluri- or multipotent stem cells and uses thereof | |
EP2990416A1 | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
DE102011118022A1 | Antibodies against the prostate-specific stem cell antigen and its use |